Valuation: Enimmune corporation

Market Cap 1.16B 36.77M 32.13M 30.2M 27.56M 51.73M 3.52B 51.74M 362M 140M 1.8B 138M 135M 5.79B P/E 2024
-11.3x
P/E 2025 -9.04x
Enterprise Value 1.11B 35.05M 30.63M 28.79M 26.27M 49.3M 3.35B 49.31M 345M 133M 1.71B 132M 129M 5.52B EV / Sales 2024
35.4x
EV / Sales 2025 29.7x
Free-Float
28.72%
Yield 2024 *
-
Yield 2025 -
1 day-2.42%
1 week+5.56%
Current month-1.82%
1 month-2.12%
3 months-1.82%
6 months-6.10%
Current year-21.60%
1 week 15.05
Extreme 15.05
17.35
1 month 15.05
Extreme 15.05
17.35
Current year 14.9
Extreme 14.9
22.15
1 year 14.9
Extreme 14.9
23.9
3 years 14.65
Extreme 14.65
49.3
5 years 14.65
Extreme 14.65
75.3
10 years 14.49
Extreme 14.49
125
Manager TitleAgeSince
Chief Executive Officer - 2019-01-06
Chief Tech/Sci/R&D Officer - 2014-07-20
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Director/Board Member - 2020-06-16
Chairman - 2019-01-06
Director/Board Member - 2014-01-01
Change 5-day change 1-year change 3-year change Capi.($)
-2.42%+5.56%-21.98%-59.42% 37.6M
-0.07%+5.66%+54.34%+113.69% 74.33B
-1.45%-0.40%+35.52%+79.18% 62.26B
-0.66%+6.97%+31.36%+23.45% 27.72B
-0.15%+0.75%-16.69%+361.67% 26.42B
+2.93%+4.32%+2.18%-3.60% 24.62B
+0.84%+6.00%+25.53%-9.89% 20.72B
+0.87%-2.52%+151.81%+328.17% 15.01B
+1.63%+2.20%+46.92%+170.72% 14.18B
+1.30%-1.61%-10.37%+815.51% 13.48B
Average +0.28%+0.28%+29.86%+181.95% 27.88B
Weighted average by Cap. +0.09%+2.10%+36.10%+149.34%

Financials

2024 2025
Net sales 39.92M 1.26M 1.1M 1.03M 944K 1.77M 120M 1.77M 12.42M 4.79M 61.51M 4.73M 4.63M 198M 48.19M 1.52M 1.33M 1.25M 1.14M 2.14M 145M 2.14M 15M 5.79M 74.27M 5.71M 5.59M 239M
Net income -158M -4.97M -4.35M -4.08M -3.73M -7M -475M -7M -49.02M -18.92M -243M -18.68M -18.27M -783M -164M -5.19M -4.53M -4.26M -3.89M -7.3M -496M -7.3M -51.14M -19.73M -253M -19.48M -19.05M -816M
Net Debt -382M -12.06M -10.54M -9.9M -9.04M -16.96M -1.15B -16.97M -119M -45.87M -589M -45.28M -44.29M -1.9B -54.59M -1.72M -1.51M -1.42M -1.29M -2.42M -165M -2.42M -16.99M -6.55M -84.13M -6.47M -6.33M -271M
Logo Enimmune corporation
ENIMMUNE CORP. is a Taiwan-based biotechnology new drug company mainly engaged in the development, produce and distribution of new drugs. The Company's new drug products include biological agents, monoclonal antibodies, vaccines, and small molecule drugs. The Company mainly conducts drug testing business, biotechnology service business, international trade business, western medicine wholesale and retail business. The product is Tuberculin PPD.
Employees
-
Date Price Change Volume
26-09-22 NT$16.15 -2.42% 33,152
26-09-21 NT$16.55 0.00% 104,310
26-09-18 NT$16.55 -2.36% 36,113
26-09-17 NT$16.95 +0.89% 83,006
26-09-16 NT$16.80 +8.04% 184,271
  1. Stock Market
  2. Stocks
  3. 6564 Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!